Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

A highly collaborative investment professional and research analyst with 10+ years of international experience in equity research, treasury operations, and trading positions across multiple asset classes at leading multinational banks Citibank and Morgan Stanley, UHNWI-backed family office and European independent equity research firm. A respectable background in equity capital markets, corporate treasury, investment banking operations, equity research analysis and portfolio management.

Algosun Global

Equity Capital Markets

Olema Pharmaceuticals Inc / Equity Capital Markets

<p>A clinical-stage biotech company Olema Pharmaceuticals priced its IPO of ~11 million shares at IPO price of $19 a share or IPO valuation of ~$800 million on a fully diluted basis. San Francisco based company develops next generation targeted therapies to treat ER+/HER2- breast cancer and signed collaboration agreements with Novartis and Pfizer to evaluate its lead product candidate OP-1250 in combination with Palbociclib, Alpelisib and Ribociclib. We estimate net proceeds from the offering to reach ~$195 million. Lead underwriters of the deal are J.P. Morgan, Jefferies, Cowen and Canaccord Genuity.</p><p>Olema Pharmaceuticals was backed by investment and venture capital firms BVF Partners L.P., Janus Capital Management, Cormorant Asset Management, Logos Capital, RA Capital Management, Wellington Management, Blackrock, Vivo Capital and Venrock. According to Crunchbase, Olema Pharmaceuticals raised ~$145M through multiple equity financing rounds.</p>

A clinical-stage biotech company Olema Pharmaceuticals priced its IPO of ~11 million shares at IPO price of $19 a share or IPO valuation of ~$800 million on a fully diluted basis. San Francisco based company develops next generation targeted therapies to treat ER+/HER2- breast cancer and signed collaboration agreements with Novartis and Pfizer to evaluate its lead product candidate OP-1250 in combination with Palbociclib, Alpelisib and Ribociclib. We estimate net proceeds from the offering to reach ~$195 million. Lead underwriters of the deal are J.P. Morgan, Jefferies, Cowen and Canaccord Genuity.Olema Pharmaceuticals was backed by investment and venture capital firms BVF Partners L.P., Janus Capital Management, Cormorant Asset Management, Logos Capital, RA Capital Management, Wellington Management, Blackrock, Vivo Capital and Venrock. According to Crunchbase, Olema Pharmaceuticals raised ~$145M through multiple equity financing rounds.

Olema Pharmaceuticals IPO. Raising Capital For Developing Innovative Therapy To Treat Breast Cancer